Arrowhead Pharmaceuticals Inc.
NASDAQ:ARWR
| Market Cap (Intraday) | 3.00B |
| Current PE | N/A |
| Forward PE | 550.75 |
| 2yr Forward PE | N/A |
| 10-Day MA | $20.98 |
| 50-Day MA | $17.68 |
| 200-Day MA | $17.49 |
Arrowhead Pharmaceuticals Inc. Stock, NASDAQ:ARWR
177 East Colorado Boulevard, Suite 700, Pasadena, California 91105
United States of America
Phone: +1.626.304.3400
Number of Employees: 609
Description
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.